The incidence of liver cancer in China is very high, because liver cancer is difficult to find in the early stage of the disease. Once the diagnosis is often in the middle and late stages, the optimal treatment time is often missed. The traditional treatment for liver cancer is surgery, radiotherapy and chemotherapy, etc. However, such treatment methods generally have a relatively high recurrence rate, and the survival rate of patients is relatively low. To prevent recurrence and metastasis of liver tumors, cell 免疫療法 現時点で試すことができます。
Due to the limitation of liver 腫瘍 size, growth location, and relationship with the position of large blood vessels and biliary tract, some patients with special small liver cancer, huge liver tumor, and middle-advanced liver cancer with multiple metastatic lesions often lose the opportunity for surgery.
However, for these patients, the expert’s approach is to first use argon-helium ultra-cold knife minimally invasive treatment, through physical freezing and thawing to destroy the cell structure of tumor tissue in a short period of time, promote tumor tissue necrosis and close tumor small blood vessels. At the same time, combined with interventional therapy, embolization of tumor large vessels and local high-concentration chemotherapy, the combination of the two therapies can inhibit the growth of liver 癌細胞 and eliminate tumor lesions in a short period of time.
In general, most of the primary 肝臓がん are large undetectable liver cancers, which are accompanied by tumor thrombi in the internal and external portal vein system. The recurrence rate within one year after radiotherapy and chemotherapy is as high as 60%, and the 3-year survival rate is less than 30%. Therefore, the most important thing for liver cancer surgery is to prevent recurrence, but traditional radiotherapy and chemotherapy have large side effects, which can easily lead to liver cirrhosis and even liver function damage.
比較的新しい治療法 - 生体細胞免疫
(CIK 細胞) は進行肝がんに大きな影響を与えます。この療法は、患者の体内に残っているがん細胞を除去し、がん細胞を識別して殺すという患者の免疫機能を回復し、それによって腫瘍の転移を予防および制御するのに役立ちます。
CIK 細胞はサイトカイン誘導性キラー細胞であり、末梢血、骨髄、または臍帯血から単離された単核細胞です。研究室で一定期間が経過すると、それらは誘導、増殖され、患者に再注入されて血液を直接殺します。また、リンパ内の腫瘍細胞も患者の免疫機能を調節し、強化します。
臨床統計によると、ステージ 9 の肝がん患者 4 人が術後に 3 サイクル以上の細胞免疫療法を受けており、これにより術後の肝がんの再発をより効果的に予防できます。治療後の平均生存期間は20か月、1年以内の再発率はわずか22.2%で、ほとんどの患者の不快感症状は改善されます。
肝腫瘍の再発と転移の予防についての上記の簡単な理解、細胞免疫療法を試すことができます。細胞免疫療法は、生物学的細胞免疫療法などの比較的新しいがん治療法であり、免疫に加えて体内に残っているがん細胞を患者が除去するのに役立ちます治療法にはがん細胞を特定して死滅させる効果があり、それによって腫瘍の広がりや転移をさらに防ぎます。
